社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Racheling89
IP属地：未知
+关注
帖子 · 17
帖子 · 17
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
Racheling89
Racheling89
·
2021-12-20
Strong buy!!! 💪🏻💪🏻
Sea Stock: Down 43% From Its High, is a Buy Now?<blockquote>Sea股票：较高点下跌43%，现在买入吗？</blockquote>
Summary Sea Limited stock has been battered recently as growth stocks sold off massively in the mar
Sea Stock: Down 43% From Its High, is a Buy Now?<blockquote>Sea股票：较高点下跌43%，现在买入吗？</blockquote>
看
2,904
回复
评论
点赞
1
编组 21备份 2
分享
举报
Racheling89
Racheling89
·
2021-11-11
To the moon!!!
非常抱歉，此主贴已删除
看
3,456
回复
1
点赞
1
编组 21备份 2
分享
举报
Racheling89
Racheling89
·
2021-08-16
prepare your $$$
U.S. stock market opens lower Monday amid weak China demand, spread of delta variant<blockquote>由于中国需求疲软和德尔塔变异毒株蔓延，美国股市周一开盘走低</blockquote>
(Aug 16) U.S. stock market opens lower Monday amid weak China demand, spread of delta variant. Dow,
U.S. stock market opens lower Monday amid weak China demand, spread of delta variant<blockquote>由于中国需求疲软和德尔塔变异毒株蔓延，美国股市周一开盘走低</blockquote>
看
2,379
回复
评论
点赞
1
编组 21备份 2
分享
举报
Racheling89
Racheling89
·
2021-08-12
Agree!!! Please like
非常抱歉，此主贴已删除
看
3,811
回复
评论
点赞
2
编组 21备份 2
分享
举报
Racheling89
Racheling89
·
2021-08-11
Nice~ please help to like~ thanks!
BioCryst shares jumped 10.49% in premarket trading,as withdrawing previous stock offering.<blockquote>BioCryst 股价在盘前交易中上涨 10.49%，撤回之前的股票发行。</blockquote>
BioCryst shares jumped 10.49% in premarket trading,as withdrawing previous stock offering. BioCryst
BioCryst shares jumped 10.49% in premarket trading,as withdrawing previous stock offering.<blockquote>BioCryst 股价在盘前交易中上涨 10.49%，撤回之前的股票发行。</blockquote>
看
2,712
回复
2
点赞
7
编组 21备份 2
分享
举报
Racheling89
Racheling89
·
2021-08-11
$CrowdStrike Holdings, Inc.(CRWD)$
Yeah!
看
2,165
回复
评论
点赞
2
编组 21备份 2
分享
举报
Racheling89
Racheling89
·
2021-08-11
Let’s hope it drops more to buy in!!
看
3,265
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Racheling89
Racheling89
·
2021-08-04
$CrowdStrike Holdings, Inc.(CRWD)$
Holding for long term
看
2,165
回复
评论
点赞
4
编组 21备份 2
分享
举报
Racheling89
Racheling89
·
2021-08-04
Nvax is running pre-market!!! Please like 👍🏻
3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>
Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021. Key Points Pfi
3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>
看
2,894
回复
1
点赞
1
编组 21备份 2
分享
举报
Racheling89
Racheling89
·
2021-06-29
Vested in Nio! Let’s see Nio in the next 5-10 years!
非常抱歉，此主贴已删除
看
2,489
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3567674825770783","uuid":"3567674825770783","gmtCreate":1604582084126,"gmtModify":1624160863141,"name":"Racheling89","pinyin":"racheling89","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/840f90f6593eaeda4fa762b7d02d006d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":20,"tweetSize":17,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.26","exceedPercentage":"60.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.38%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":693163611,"gmtCreate":1639987117091,"gmtModify":1639987117158,"author":{"id":"3567674825770783","authorId":"3567674825770783","name":"Racheling89","avatar":"https://static.tigerbbs.com/840f90f6593eaeda4fa762b7d02d006d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567674825770783","idStr":"3567674825770783"},"themes":[],"title":"","htmlText":"Strong buy!!! 💪🏻💪🏻","listText":"Strong buy!!! 💪🏻💪🏻","text":"Strong buy!!! 💪🏻💪🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693163611","repostId":"1109541249","repostType":2,"repost":{"id":"1109541249","kind":"news","pubTimestamp":1639972523,"share":"https://www.laohunote.com/m/news/1109541249?lang=zh_CN&edition=full","pubTime":"2021-12-20 11:55","market":"us","language":"en","title":"Sea Stock: Down 43% From Its High, is a Buy Now?<blockquote>Sea股票：较高点下跌43%，现在买入吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109541249","media":"Seeking Alpha","summary":"Summary\n\nSea Limited stock has been battered recently as growth stocks sold off massively in the mar","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul> <li>Sea Limited stock has been battered recently as growth stocks sold off massively in the market.</li> <li>However, we believe that the fundamental thesis on its rapid growth remains robust.</li> <li>We discuss why investors should capitalize on its recent significant correction to add exposure.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/aa5cbe0a30acc723a2c6f62300024002\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>kokkai/iStock Unreleased via Getty Images</span></p><p><blockquote><ul><li>由于市场成长型股票大幅抛售，Sea Limited 的股票最近遭受重创。</li><li>然而，我们认为其快速增长的基本论点仍然稳固。</li><li>我们讨论为什么投资者应该利用最近的重大调整来增加风险敞口。</li></ul><p class=\"t-img-caption\"><span>kokkai/iStock 未通过 Getty Images 发布</span></p></blockquote></p><p> <b>Investment Thesis</b></p><p><blockquote><b>投资论文</b></blockquote></p><p> Sea Limited(NYSE:SE) stock is one of our highest conviction growth stocks that has been severely battered over the last month. Since its recent all-time high (ATH) in October, its price has dropped by a dramatic 43%. Many reasons have been presented on why the stock has fallen. We exhort investors not to read too much into them. We believe nothing material has changed from its fundamental thesis. The stock has had a remarkable run in 2021 relative to its gaming peers or e-tailer peers. Therefore, profit-taking of this extent should not be surprising as fear struck growth stocks.</p><p><blockquote>Sea Limited（纽约证券交易所股票代码：SE）股票是我们最相信的成长型股票之一，在上个月遭受了严重打击。自 10 月份创下历史新高 (ATH) 以来，其价格已大幅下跌 43%。关于该股下跌的原因有很多。我们建议投资者不要过多地解读它们。我们认为它的基本论点没有任何实质性的改变。相对于游戏同行或电子零售商同行，该股在 2021 年表现出色。因此，当恐惧袭击成长型股票时，这种程度的获利了结并不奇怪。</blockquote></p><p> Moreover, the recent significant correction in growth stocks across the market has also hit SE stock hard. But, we are not concerned. Significant volatility will always be a factor influencing the performance of growth stocks like SE in the short term.</p><p><blockquote>此外，近期全市场成长股的大幅回调也对SE股造成了沉重打击。但是，我们并不担心。短期内，显著的波动性始终是影响SE等成长股表现的一个因素。</blockquote></p><p> Notably, we observed that the consensus target price on SE stock had been revised upwards since its FQ3 report card. Moreover, the gap between its price target and its current stock price has been greater than its last significant correction in April/May.</p><p><blockquote>值得注意的是，我们观察到，自第三季度报告以来，SE 股票的一致目标价已被上调。此外，其目标价与其当前股价之间的差距已经大于其上一次在4月/5月的大幅调整。</blockquote></p><p> Our internal DCF valuation model also points to a stock that is now significantly undervalued. Thanks to the market's myopia, we have been presented with another fantastic opportunity since April/May to add SE stock with great fervor again.</p><p><blockquote>我们的内部 DCF 估值模型还指出了一只目前被严重低估的股票。由于市场的短视，自4月/5月以来，我们又迎来了一个绝佳的机会，再次以极大的热情增持SE股票。</blockquote></p><p> We discuss why we think investors should not miss this incredible opportunity to add exposure to an outstanding growth stock.</p><p><blockquote>我们讨论为什么我们认为投资者不应该错过这个难以置信的机会来增加对优秀成长型股票的投资。</blockquote></p><p> <b>SE Stock YTD Performance</b></p><p><blockquote><b>SE 股票年初至今表现</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6c191d1f0f6a10e392845cdbda1264aa\" tg-width=\"640\" tg-height=\"331\" referrerpolicy=\"no-referrer\"><span>SE stock YTD performance (as of 17 December'21).</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票年初至今表现（截至21年12月17日）。</span></p></blockquote></p><p> As a result of the significant correction recently, SE stock's YTD return has dropped to 6.9%, thus underperforming the market. Notably, its YTD gain was as high as 80% in October/early November. Despite that, the stock is still outperforming its e-tailer and gaming peers, as shown above.</p><p><blockquote>由于最近的大幅调整，SE股票的年初至今回报率已降至6.9%，因此跑输大盘。值得注意的是，其年初至今的涨幅在10月/11月初高达80%。尽管如此，如上图所示，该股的表现仍然优于电子零售商和游戏同行。</blockquote></p><p> <b>Sea Stock Estimates Have Consistently Been Revised Upwards</b></p><p><blockquote><b>Sea 股票预测一直被上调</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8555128e2a30e924dd6c2dd162a27eea\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised revenue mean consensus estimates. Data source: S&P Capital IQ, Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>Sea Limited 修订后的收入平均共识估计。数据来源：标普资本智商、Seeking Alpha</span></p></blockquote></p><p> Readers can quickly observe that the company's revenue consensus estimates for FY21-23 have consistently been revised upwards over the last five months. These revisions lend credence to the robust growth prospects of the company over the next two years. Notably, Sea Limited's revenue is estimated to increase at a phenomenal CAGR of 42.8% through FY23.</p><p><blockquote>读者可以很快观察到，该公司对 21-23 财年的收入共识预期在过去五个月中一直被上调。这些修订为公司未来两年强劲的增长前景提供了可信度。值得注意的是，Sea Limited 的收入预计将通过2023财年以 42.8% 的惊人复合年增长率增长。</blockquote></p><p> There were concerns over the growth rates of its Garena gaming arm in its FQ3 report card.We also explained in our previous article that Sea Limited has clearly explained that investors should expect normalization in Garena's growth after two spectacular years. However, its monetization capability continues to dazzle. Therefore, we are confident that Garena can continue its robust monetization strategies moving forward.</p><p><blockquote>第三季度成绩单中对 Garena 游戏部门的增长率表示担忧。我们还在之前的文章中解释说，Sea Limited 已明确解释说，投资者应该期待 Garena 在经历了辉煌的两年后增长恢复正常。然而，其变现能力继续令人眼花缭乱。因此，我们相信 Garena 能够继续其稳健的货币化战略。</blockquote></p><p> Moreover, data from Sensor Tower's recent gaming statistics continue to point to sturdy performance from its Free Fire game. It continues to be ranked among the top ten mobile games in terms of overall gaming revenue in November. Moreover, it's also ranked#2 in overall downloadsacross both the App Store and Google Play. Notably, it's also among eight games globally whose annual revenue crossed $1B as of 14 December. Therefore, we think the sentiments and chatter about Free Fire's \"one-shot wonder\" have been overblown.</p><p><blockquote>此外，Sensor Tower最近的游戏统计数据继续表明其Free Fire游戏的强劲表现。就11月游戏整体收入而言，它继续位居移动游戏前十。此外，它在App Store和Google Play的总下载量中也排名第二。值得注意的是，截至12月14日，它也是全球八款年收入超过10亿美元的游戏之一。因此，我们认为关于Free Fire“一次性奇迹”的情绪和喋喋不休被夸大了。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/51247ba1efd7fa6d333b482446e94c9a\" tg-width=\"515\" tg-height=\"380\" referrerpolicy=\"no-referrer\"><span>Global games market forecast. Source: Google, Newzoo</span></p><p><blockquote><p class=\"t-img-caption\"><span>全球游戏市场预测。资料来源：谷歌、Newzoo</span></p></blockquote></p><p></p><p> In addition, the global gaming market is estimated to experience a slight decline to $175.8B after last year's massive 23% growth to $177.8B. However, given Garena's impressive growth in FY21 despite the decline in the global market, we believe it validates its business model and prospects. Notably, the gaming market is expected to reverse its decline moving forward. Therefore, Garena's leadership in mobile gaming could continue to propel its growth underpinned by the recovery in the global gaming market.</p><p><blockquote>此外，全球博彩市场在去年大幅增长 23% 至 177.8B 美元后，预计将略有下降至 175.8B 美元。然而，鉴于尽管全球市场下滑，Garena 在 2021 财年仍实现了令人印象深刻的增长，我们相信这验证了其商业模式和前景。值得注意的是，博彩市场有望在未来扭转颓势。因此，在全球游戏市场复苏的推动下，Garena 在移动游戏领域的领导地位可能会继续推动其增长。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0a0612da9a19f7b7198d43213b4f4470\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Shopee adjusted EBITDA per order. Data source: Company filings</span></p><p><blockquote><p class=\"t-img-caption\"><span>Shopee 调整了每个订单的 EBITDA。数据来源：公司文件</span></p></blockquote></p><p> But, some investors may have been spooked by Shopee's (Sea Limited's e-commerce arm) continued expansion into new geographical markets. Notably, Shopee continues to report adjusted EBITDA loss per order, as shown above. Therefore, some investors might have been concerned about whether the company's plate is getting too much to handle. Over the last three months, the company has entered into new markets such as India, France, Spain, and Poland. They are in addition to its battle with MercadoLibre (MELI) in Latin America, particularly Brazil. As a result, there are concerns on whether Sea Limited could continue its adroit execution in these markets while still making losses. We believe such concerns are valid. However, Sea Limited has shown its tremendous capability in penetrating the most important markets where the incumbents have strong leadership. It includes Lazada (BABA) in Southeast Asia, MercadoLibre in Brazil, and Tokopedia in Indonesia. Shopee was never the first-mover. But, it took advantage as the \"late-comer\" as it sought to compete with the incumbents. It's important to note that Sea Limited is not averse to competition. It has thrived against the incumbents and has made the e-commerce space in these geographical regions much more competitive.</p><p><blockquote>但是，一些投资者可能对 Shopee（Sea Limited 的电子商务部门）向新地理市场的持续扩张感到害怕。值得注意的是，Shopee 继续报告每个订单的调整后 EBITDA 损失，如上所示。因此，一些投资者可能担心该公司的盘子是否有太多难以处理。在过去的三个月里，该公司进入了印度、法国、西班牙和波兰等新市场。此外，它还在拉丁美洲，特别是巴西与自由市场（MELI）的斗争。因此，人们担心 Sea Limited 能否在这些市场继续其娴熟的执行，同时仍在亏损。我们认为这种担忧是合理的。然而，Sea Limited 在渗透现有企业拥有强大领导地位的最重要市场方面表现出了巨大的能力。它包括东南亚的Lazada（BABA）、巴西的MercadoLibre和印度尼西亚的Tokopedia。Shopee从来都不是先行者。但是，它利用了“后来者”的优势，试图与现任者竞争。值得注意的是，Sea Limited并不反对竞争。它与现有企业相比蓬勃发展，并使这些地理区域的电子商务领域更具竞争力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80938433e2d55307ca40000eeea2a26f\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised adjusted EPS mean consensus estimates. Data source: S&P Capital IQ, Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>Sea Limited 修订调整后每股收益平均共识估计。数据来源：标普资本智商、Seeking Alpha</span></p></blockquote></p><p> Nevertheless, the road towards profitability might be stretched further due to its e-commerce expansion. Readers can quickly glance over the chart above, where its adjusted EPS estimates have been revised downwards through FY23 over the last five months. However, we believe that if you are a long-term investor with a five-year horizon at least, it's not a cause for concern. Earlier investors in Sea Limited can keenly recall the company's massive adjusted EBITDA per order losses, as seen in the previous chart. Shopee has scaled tremendously over the last five years and has improved its operating leverage further. But, it's important to note that it takes time to scale up. Therefore, earlier losses in new geographical markets are expected. But, management has demonstrated its execution capability over the last three years. Considering its much reduced adjusted EBITDA losses over the previous few years, we believe that Shopee is even better positioned than before to navigate its expansion.</p><p><blockquote>然而，由于其电子商务的扩张，盈利之路可能会进一步延长。读者可以快速浏览上图，其中2023财年在过去五个月中对其调整后的每股收益预期进行了下调。然而，我们认为，如果您是至少有五年期限的长期投资者，则无需担心。Sea Limited 的早期投资者可以清楚地回忆起该公司每笔订单的巨额调整后 EBITDA 损失，如上图表所示。Shopee 在过去五年中规模巨大，并进一步提高了运营杠杆。但是，重要的是要注意，扩大规模需要时间。因此，预计新地理市场的早期亏损。但是，管理层在过去三年中已经展示了其执行能力。考虑到过去几年调整后 EBITDA 亏损大幅减少，我们相信 Shopee 比以前更有能力进行扩张。</blockquote></p><p> <b>So, is SE Stock a Buy Now?</b></p><p><blockquote><b>那么，SE 股票现在值得买入吗？</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3dbc835e49ded8a7a0e5f4fcc9e10649\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\"><span>SE stock EV/NTM Revenue 4Y mean.</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票EV/NTM收入4年平均值。</span></p></blockquote></p><p> SE stock is trading at an EV/NTM Revenue of 8.3x. Therefore, it has brought it back to its 4Y NTM revenue multiple mean of 8.6x. We believe there's a fantastic opportunity right now as the market has undoubtedly overreacted. As demonstrated clearly, SE is still expected to generate massive revenue growth moving ahead, even though it means the road to profitability gets further extended.</p><p><blockquote>SE 股票的 EV/NTM 收入为 8.3 倍。因此，它已将其恢复到 4 年 NTM 收入倍数平均值 8.6 倍。我们相信现在有一个绝佳的机会，因为市场无疑已经反应过度。正如清楚地表明的那样，SE 仍有望在未来实现巨大的收入增长，尽管这意味着盈利之路将进一步延长。</blockquote></p><p> Considering its FY23 revenue estimate, SE stock is trading at just 5.8x FY23 revenue. No one can accurately predict where the stock will be headed over the next few months. But, we think it represents a tremendous opportunity right now.</p><p><blockquote>考虑到其2023财年收入预期，SE 股票的交易价格仅为2023财年收入的 5.8 倍。没有人能够准确预测该股未来几个月的走势。但是，我们认为现在这是一个巨大的机会。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3bea18a0bdfd970ea640308dc35e099c\" tg-width=\"635\" tg-height=\"362\" referrerpolicy=\"no-referrer\"><span>SE stock price target Vs. actual price trend. Source: Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE 股价目标与实际价格趋势。来源：Seeking Alpha</span></p></blockquote></p><p></p><p> Moreover, readers can observe that the valuation gap between SE stock's consensus price target (PT) of $405.87 and its current price has never been more significant in a while. It's even more pronounced than its last significant correction in April/May. Notably, the consensus price target has been revised upwards despite the so-called \"gaming headwinds.\" And, if you look at the price chart, SE stock price has followed the revised PT trend very consistently over time. Therefore, the current price could be one of the most significant discounts you could observe in a long time.</p><p><blockquote>此外，读者可以观察到，SE 股票的共识目标价 (PT) 405.87 美元与其当前价格之间的估值差距一段时间以来从未如此显着。这比4月/5月的上一次大幅调整更加明显。值得注意的是，尽管存在所谓的“博彩逆风”，但共识目标价格已被上调。而且，如果你看一下价格图表，随着时间的推移，SE 股价一直非常一致地遵循修订后的 PT 趋势。因此，当前价格可能是您在很长一段时间内观察到的最大折扣之一。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/939a544ab94c9e2a2b8a6db943703b39\" tg-width=\"910\" tg-height=\"602\" referrerpolicy=\"no-referrer\"><span>SE stock DCF valuation model. Data source: S&P Capital IQ, company filings, author</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票DCF估值模型。数据来源：S&P Capital IQ、公司文件、作者</span></p></blockquote></p><p> Our DCF model also shows that SE stock is now significantly undervalued with an implied fair value of $371.46. We have also used reasonable estimates in our model. Moreover, we believe that SE will continue to gain significant operating leverage as it scales in the new markets. We estimate that its adjusted EBITDA margins could reach 15% by FY25.</p><p><blockquote>我们的 DCF 模型还显示，SE 股票目前被严重低估，隐含公允价值为 371.46 美元。我们在模型中也使用了合理的估计。此外，我们相信，随着SE在新市场的扩大规模，SE将继续获得显著的运营杠杆。我们预计，到 2025 财年，其调整后 EBITDA 利润率可能达到 15%。</blockquote></p><p> Lastly, the stock is also testing a critical support level that has strongly underpinned the stock's advance since early 2021. Therefore, there are sufficient reasons to believe that the current entry point to add exposure to SE stock seems very attractive now.</p><p><blockquote>最后，该股还在测试一个关键支撑位，该支撑位自 2021 年初以来一直有力地支撑着该股的上涨。因此，有足够的理由相信，目前增加SE股票敞口的切入点现在看来非常有吸引力。</blockquote></p><p> Consequently,<i>we revise our rating on SE stock to Strong Buy</i>.</p><p><blockquote>因此，<i>我们将 SE 股票评级修改为强力买入</i>.</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Stock: Down 43% From Its High, is a Buy Now?<blockquote>Sea股票：较高点下跌43%，现在买入吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Stock: Down 43% From Its High, is a Buy Now?<blockquote>Sea股票：较高点下跌43%，现在买入吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-20 11:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul> <li>Sea Limited stock has been battered recently as growth stocks sold off massively in the market.</li> <li>However, we believe that the fundamental thesis on its rapid growth remains robust.</li> <li>We discuss why investors should capitalize on its recent significant correction to add exposure.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/aa5cbe0a30acc723a2c6f62300024002\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>kokkai/iStock Unreleased via Getty Images</span></p><p><blockquote><ul><li>由于市场成长型股票大幅抛售，Sea Limited 的股票最近遭受重创。</li><li>然而，我们认为其快速增长的基本论点仍然稳固。</li><li>我们讨论为什么投资者应该利用最近的重大调整来增加风险敞口。</li></ul><p class=\"t-img-caption\"><span>kokkai/iStock 未通过 Getty Images 发布</span></p></blockquote></p><p> <b>Investment Thesis</b></p><p><blockquote><b>投资论文</b></blockquote></p><p> Sea Limited(NYSE:SE) stock is one of our highest conviction growth stocks that has been severely battered over the last month. Since its recent all-time high (ATH) in October, its price has dropped by a dramatic 43%. Many reasons have been presented on why the stock has fallen. We exhort investors not to read too much into them. We believe nothing material has changed from its fundamental thesis. The stock has had a remarkable run in 2021 relative to its gaming peers or e-tailer peers. Therefore, profit-taking of this extent should not be surprising as fear struck growth stocks.</p><p><blockquote>Sea Limited（纽约证券交易所股票代码：SE）股票是我们最相信的成长型股票之一，在上个月遭受了严重打击。自 10 月份创下历史新高 (ATH) 以来，其价格已大幅下跌 43%。关于该股下跌的原因有很多。我们建议投资者不要过多地解读它们。我们认为它的基本论点没有任何实质性的改变。相对于游戏同行或电子零售商同行，该股在 2021 年表现出色。因此，当恐惧袭击成长型股票时，这种程度的获利了结并不奇怪。</blockquote></p><p> Moreover, the recent significant correction in growth stocks across the market has also hit SE stock hard. But, we are not concerned. Significant volatility will always be a factor influencing the performance of growth stocks like SE in the short term.</p><p><blockquote>此外，近期全市场成长股的大幅回调也对SE股造成了沉重打击。但是，我们并不担心。短期内，显著的波动性始终是影响SE等成长股表现的一个因素。</blockquote></p><p> Notably, we observed that the consensus target price on SE stock had been revised upwards since its FQ3 report card. Moreover, the gap between its price target and its current stock price has been greater than its last significant correction in April/May.</p><p><blockquote>值得注意的是，我们观察到，自第三季度报告以来，SE 股票的一致目标价已被上调。此外，其目标价与其当前股价之间的差距已经大于其上一次在4月/5月的大幅调整。</blockquote></p><p> Our internal DCF valuation model also points to a stock that is now significantly undervalued. Thanks to the market's myopia, we have been presented with another fantastic opportunity since April/May to add SE stock with great fervor again.</p><p><blockquote>我们的内部 DCF 估值模型还指出了一只目前被严重低估的股票。由于市场的短视，自4月/5月以来，我们又迎来了一个绝佳的机会，再次以极大的热情增持SE股票。</blockquote></p><p> We discuss why we think investors should not miss this incredible opportunity to add exposure to an outstanding growth stock.</p><p><blockquote>我们讨论为什么我们认为投资者不应该错过这个难以置信的机会来增加对优秀成长型股票的投资。</blockquote></p><p> <b>SE Stock YTD Performance</b></p><p><blockquote><b>SE 股票年初至今表现</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6c191d1f0f6a10e392845cdbda1264aa\" tg-width=\"640\" tg-height=\"331\" referrerpolicy=\"no-referrer\"><span>SE stock YTD performance (as of 17 December'21).</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票年初至今表现（截至21年12月17日）。</span></p></blockquote></p><p> As a result of the significant correction recently, SE stock's YTD return has dropped to 6.9%, thus underperforming the market. Notably, its YTD gain was as high as 80% in October/early November. Despite that, the stock is still outperforming its e-tailer and gaming peers, as shown above.</p><p><blockquote>由于最近的大幅调整，SE股票的年初至今回报率已降至6.9%，因此跑输大盘。值得注意的是，其年初至今的涨幅在10月/11月初高达80%。尽管如此，如上图所示，该股的表现仍然优于电子零售商和游戏同行。</blockquote></p><p> <b>Sea Stock Estimates Have Consistently Been Revised Upwards</b></p><p><blockquote><b>Sea 股票预测一直被上调</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8555128e2a30e924dd6c2dd162a27eea\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised revenue mean consensus estimates. Data source: S&P Capital IQ, Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>Sea Limited 修订后的收入平均共识估计。数据来源：标普资本智商、Seeking Alpha</span></p></blockquote></p><p> Readers can quickly observe that the company's revenue consensus estimates for FY21-23 have consistently been revised upwards over the last five months. These revisions lend credence to the robust growth prospects of the company over the next two years. Notably, Sea Limited's revenue is estimated to increase at a phenomenal CAGR of 42.8% through FY23.</p><p><blockquote>读者可以很快观察到，该公司对 21-23 财年的收入共识预期在过去五个月中一直被上调。这些修订为公司未来两年强劲的增长前景提供了可信度。值得注意的是，Sea Limited 的收入预计将通过2023财年以 42.8% 的惊人复合年增长率增长。</blockquote></p><p> There were concerns over the growth rates of its Garena gaming arm in its FQ3 report card.We also explained in our previous article that Sea Limited has clearly explained that investors should expect normalization in Garena's growth after two spectacular years. However, its monetization capability continues to dazzle. Therefore, we are confident that Garena can continue its robust monetization strategies moving forward.</p><p><blockquote>第三季度成绩单中对 Garena 游戏部门的增长率表示担忧。我们还在之前的文章中解释说，Sea Limited 已明确解释说，投资者应该期待 Garena 在经历了辉煌的两年后增长恢复正常。然而，其变现能力继续令人眼花缭乱。因此，我们相信 Garena 能够继续其稳健的货币化战略。</blockquote></p><p> Moreover, data from Sensor Tower's recent gaming statistics continue to point to sturdy performance from its Free Fire game. It continues to be ranked among the top ten mobile games in terms of overall gaming revenue in November. Moreover, it's also ranked#2 in overall downloadsacross both the App Store and Google Play. Notably, it's also among eight games globally whose annual revenue crossed $1B as of 14 December. Therefore, we think the sentiments and chatter about Free Fire's \"one-shot wonder\" have been overblown.</p><p><blockquote>此外，Sensor Tower最近的游戏统计数据继续表明其Free Fire游戏的强劲表现。就11月游戏整体收入而言，它继续位居移动游戏前十。此外，它在App Store和Google Play的总下载量中也排名第二。值得注意的是，截至12月14日，它也是全球八款年收入超过10亿美元的游戏之一。因此，我们认为关于Free Fire“一次性奇迹”的情绪和喋喋不休被夸大了。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/51247ba1efd7fa6d333b482446e94c9a\" tg-width=\"515\" tg-height=\"380\" referrerpolicy=\"no-referrer\"><span>Global games market forecast. Source: Google, Newzoo</span></p><p><blockquote><p class=\"t-img-caption\"><span>全球游戏市场预测。资料来源：谷歌、Newzoo</span></p></blockquote></p><p></p><p> In addition, the global gaming market is estimated to experience a slight decline to $175.8B after last year's massive 23% growth to $177.8B. However, given Garena's impressive growth in FY21 despite the decline in the global market, we believe it validates its business model and prospects. Notably, the gaming market is expected to reverse its decline moving forward. Therefore, Garena's leadership in mobile gaming could continue to propel its growth underpinned by the recovery in the global gaming market.</p><p><blockquote>此外，全球博彩市场在去年大幅增长 23% 至 177.8B 美元后，预计将略有下降至 175.8B 美元。然而，鉴于尽管全球市场下滑，Garena 在 2021 财年仍实现了令人印象深刻的增长，我们相信这验证了其商业模式和前景。值得注意的是，博彩市场有望在未来扭转颓势。因此，在全球游戏市场复苏的推动下，Garena 在移动游戏领域的领导地位可能会继续推动其增长。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0a0612da9a19f7b7198d43213b4f4470\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Shopee adjusted EBITDA per order. Data source: Company filings</span></p><p><blockquote><p class=\"t-img-caption\"><span>Shopee 调整了每个订单的 EBITDA。数据来源：公司文件</span></p></blockquote></p><p> But, some investors may have been spooked by Shopee's (Sea Limited's e-commerce arm) continued expansion into new geographical markets. Notably, Shopee continues to report adjusted EBITDA loss per order, as shown above. Therefore, some investors might have been concerned about whether the company's plate is getting too much to handle. Over the last three months, the company has entered into new markets such as India, France, Spain, and Poland. They are in addition to its battle with MercadoLibre (MELI) in Latin America, particularly Brazil. As a result, there are concerns on whether Sea Limited could continue its adroit execution in these markets while still making losses. We believe such concerns are valid. However, Sea Limited has shown its tremendous capability in penetrating the most important markets where the incumbents have strong leadership. It includes Lazada (BABA) in Southeast Asia, MercadoLibre in Brazil, and Tokopedia in Indonesia. Shopee was never the first-mover. But, it took advantage as the \"late-comer\" as it sought to compete with the incumbents. It's important to note that Sea Limited is not averse to competition. It has thrived against the incumbents and has made the e-commerce space in these geographical regions much more competitive.</p><p><blockquote>但是，一些投资者可能对 Shopee（Sea Limited 的电子商务部门）向新地理市场的持续扩张感到害怕。值得注意的是，Shopee 继续报告每个订单的调整后 EBITDA 损失，如上所示。因此，一些投资者可能担心该公司的盘子是否有太多难以处理。在过去的三个月里，该公司进入了印度、法国、西班牙和波兰等新市场。此外，它还在拉丁美洲，特别是巴西与自由市场（MELI）的斗争。因此，人们担心 Sea Limited 能否在这些市场继续其娴熟的执行，同时仍在亏损。我们认为这种担忧是合理的。然而，Sea Limited 在渗透现有企业拥有强大领导地位的最重要市场方面表现出了巨大的能力。它包括东南亚的Lazada（BABA）、巴西的MercadoLibre和印度尼西亚的Tokopedia。Shopee从来都不是先行者。但是，它利用了“后来者”的优势，试图与现任者竞争。值得注意的是，Sea Limited并不反对竞争。它与现有企业相比蓬勃发展，并使这些地理区域的电子商务领域更具竞争力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80938433e2d55307ca40000eeea2a26f\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised adjusted EPS mean consensus estimates. Data source: S&P Capital IQ, Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>Sea Limited 修订调整后每股收益平均共识估计。数据来源：标普资本智商、Seeking Alpha</span></p></blockquote></p><p> Nevertheless, the road towards profitability might be stretched further due to its e-commerce expansion. Readers can quickly glance over the chart above, where its adjusted EPS estimates have been revised downwards through FY23 over the last five months. However, we believe that if you are a long-term investor with a five-year horizon at least, it's not a cause for concern. Earlier investors in Sea Limited can keenly recall the company's massive adjusted EBITDA per order losses, as seen in the previous chart. Shopee has scaled tremendously over the last five years and has improved its operating leverage further. But, it's important to note that it takes time to scale up. Therefore, earlier losses in new geographical markets are expected. But, management has demonstrated its execution capability over the last three years. Considering its much reduced adjusted EBITDA losses over the previous few years, we believe that Shopee is even better positioned than before to navigate its expansion.</p><p><blockquote>然而，由于其电子商务的扩张，盈利之路可能会进一步延长。读者可以快速浏览上图，其中2023财年在过去五个月中对其调整后的每股收益预期进行了下调。然而，我们认为，如果您是至少有五年期限的长期投资者，则无需担心。Sea Limited 的早期投资者可以清楚地回忆起该公司每笔订单的巨额调整后 EBITDA 损失，如上图表所示。Shopee 在过去五年中规模巨大，并进一步提高了运营杠杆。但是，重要的是要注意，扩大规模需要时间。因此，预计新地理市场的早期亏损。但是，管理层在过去三年中已经展示了其执行能力。考虑到过去几年调整后 EBITDA 亏损大幅减少，我们相信 Shopee 比以前更有能力进行扩张。</blockquote></p><p> <b>So, is SE Stock a Buy Now?</b></p><p><blockquote><b>那么，SE 股票现在值得买入吗？</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3dbc835e49ded8a7a0e5f4fcc9e10649\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\"><span>SE stock EV/NTM Revenue 4Y mean.</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票EV/NTM收入4年平均值。</span></p></blockquote></p><p> SE stock is trading at an EV/NTM Revenue of 8.3x. Therefore, it has brought it back to its 4Y NTM revenue multiple mean of 8.6x. We believe there's a fantastic opportunity right now as the market has undoubtedly overreacted. As demonstrated clearly, SE is still expected to generate massive revenue growth moving ahead, even though it means the road to profitability gets further extended.</p><p><blockquote>SE 股票的 EV/NTM 收入为 8.3 倍。因此，它已将其恢复到 4 年 NTM 收入倍数平均值 8.6 倍。我们相信现在有一个绝佳的机会，因为市场无疑已经反应过度。正如清楚地表明的那样，SE 仍有望在未来实现巨大的收入增长，尽管这意味着盈利之路将进一步延长。</blockquote></p><p> Considering its FY23 revenue estimate, SE stock is trading at just 5.8x FY23 revenue. No one can accurately predict where the stock will be headed over the next few months. But, we think it represents a tremendous opportunity right now.</p><p><blockquote>考虑到其2023财年收入预期，SE 股票的交易价格仅为2023财年收入的 5.8 倍。没有人能够准确预测该股未来几个月的走势。但是，我们认为现在这是一个巨大的机会。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3bea18a0bdfd970ea640308dc35e099c\" tg-width=\"635\" tg-height=\"362\" referrerpolicy=\"no-referrer\"><span>SE stock price target Vs. actual price trend. Source: Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE 股价目标与实际价格趋势。来源：Seeking Alpha</span></p></blockquote></p><p></p><p> Moreover, readers can observe that the valuation gap between SE stock's consensus price target (PT) of $405.87 and its current price has never been more significant in a while. It's even more pronounced than its last significant correction in April/May. Notably, the consensus price target has been revised upwards despite the so-called \"gaming headwinds.\" And, if you look at the price chart, SE stock price has followed the revised PT trend very consistently over time. Therefore, the current price could be one of the most significant discounts you could observe in a long time.</p><p><blockquote>此外，读者可以观察到，SE 股票的共识目标价 (PT) 405.87 美元与其当前价格之间的估值差距一段时间以来从未如此显着。这比4月/5月的上一次大幅调整更加明显。值得注意的是，尽管存在所谓的“博彩逆风”，但共识目标价格已被上调。而且，如果你看一下价格图表，随着时间的推移，SE 股价一直非常一致地遵循修订后的 PT 趋势。因此，当前价格可能是您在很长一段时间内观察到的最大折扣之一。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/939a544ab94c9e2a2b8a6db943703b39\" tg-width=\"910\" tg-height=\"602\" referrerpolicy=\"no-referrer\"><span>SE stock DCF valuation model. Data source: S&P Capital IQ, company filings, author</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票DCF估值模型。数据来源：S&P Capital IQ、公司文件、作者</span></p></blockquote></p><p> Our DCF model also shows that SE stock is now significantly undervalued with an implied fair value of $371.46. We have also used reasonable estimates in our model. Moreover, we believe that SE will continue to gain significant operating leverage as it scales in the new markets. We estimate that its adjusted EBITDA margins could reach 15% by FY25.</p><p><blockquote>我们的 DCF 模型还显示，SE 股票目前被严重低估，隐含公允价值为 371.46 美元。我们在模型中也使用了合理的估计。此外，我们相信，随着SE在新市场的扩大规模，SE将继续获得显著的运营杠杆。我们预计，到 2025 财年，其调整后 EBITDA 利润率可能达到 15%。</blockquote></p><p> Lastly, the stock is also testing a critical support level that has strongly underpinned the stock's advance since early 2021. Therefore, there are sufficient reasons to believe that the current entry point to add exposure to SE stock seems very attractive now.</p><p><blockquote>最后，该股还在测试一个关键支撑位，该支撑位自 2021 年初以来一直有力地支撑着该股的上涨。因此，有足够的理由相信，目前增加SE股票敞口的切入点现在看来非常有吸引力。</blockquote></p><p> Consequently,<i>we revise our rating on SE stock to Strong Buy</i>.</p><p><blockquote>因此，<i>我们将 SE 股票评级修改为强力买入</i>.</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4475931-sea-se-down-significantly-stock-strong-buy\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"source_url":"https://seekingalpha.com/article/4475931-sea-se-down-significantly-stock-strong-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109541249","content_text":"Summary\n\nSea Limited stock has been battered recently as growth stocks sold off massively in the market.\nHowever, we believe that the fundamental thesis on its rapid growth remains robust.\nWe discuss why investors should capitalize on its recent significant correction to add exposure.\n\nkokkai/iStock Unreleased via Getty Images\nInvestment Thesis\nSea Limited(NYSE:SE) stock is one of our highest conviction growth stocks that has been severely battered over the last month. Since its recent all-time high (ATH) in October, its price has dropped by a dramatic 43%. Many reasons have been presented on why the stock has fallen. We exhort investors not to read too much into them. We believe nothing material has changed from its fundamental thesis. The stock has had a remarkable run in 2021 relative to its gaming peers or e-tailer peers. Therefore, profit-taking of this extent should not be surprising as fear struck growth stocks.\nMoreover, the recent significant correction in growth stocks across the market has also hit SE stock hard. But, we are not concerned. Significant volatility will always be a factor influencing the performance of growth stocks like SE in the short term.\nNotably, we observed that the consensus target price on SE stock had been revised upwards since its FQ3 report card. Moreover, the gap between its price target and its current stock price has been greater than its last significant correction in April/May.\nOur internal DCF valuation model also points to a stock that is now significantly undervalued. Thanks to the market's myopia, we have been presented with another fantastic opportunity since April/May to add SE stock with great fervor again.\nWe discuss why we think investors should not miss this incredible opportunity to add exposure to an outstanding growth stock.\nSE Stock YTD Performance\nSE stock YTD performance (as of 17 December'21).\nAs a result of the significant correction recently, SE stock's YTD return has dropped to 6.9%, thus underperforming the market. Notably, its YTD gain was as high as 80% in October/early November. Despite that, the stock is still outperforming its e-tailer and gaming peers, as shown above.\nSea Stock Estimates Have Consistently Been Revised Upwards\nSea Limited revised revenue mean consensus estimates. Data source: S&P Capital IQ, Seeking Alpha\nReaders can quickly observe that the company's revenue consensus estimates for FY21-23 have consistently been revised upwards over the last five months. These revisions lend credence to the robust growth prospects of the company over the next two years. Notably, Sea Limited's revenue is estimated to increase at a phenomenal CAGR of 42.8% through FY23.\nThere were concerns over the growth rates of its Garena gaming arm in its FQ3 report card.We also explained in our previous article that Sea Limited has clearly explained that investors should expect normalization in Garena's growth after two spectacular years. However, its monetization capability continues to dazzle. Therefore, we are confident that Garena can continue its robust monetization strategies moving forward.\nMoreover, data from Sensor Tower's recent gaming statistics continue to point to sturdy performance from its Free Fire game. It continues to be ranked among the top ten mobile games in terms of overall gaming revenue in November. Moreover, it's also ranked#2 in overall downloadsacross both the App Store and Google Play. Notably, it's also among eight games globally whose annual revenue crossed $1B as of 14 December. Therefore, we think the sentiments and chatter about Free Fire's \"one-shot wonder\" have been overblown.\nGlobal games market forecast. Source: Google, Newzoo\nIn addition, the global gaming market is estimated to experience a slight decline to $175.8B after last year's massive 23% growth to $177.8B. However, given Garena's impressive growth in FY21 despite the decline in the global market, we believe it validates its business model and prospects. Notably, the gaming market is expected to reverse its decline moving forward. Therefore, Garena's leadership in mobile gaming could continue to propel its growth underpinned by the recovery in the global gaming market.\nShopee adjusted EBITDA per order. Data source: Company filings\nBut, some investors may have been spooked by Shopee's (Sea Limited's e-commerce arm) continued expansion into new geographical markets. Notably, Shopee continues to report adjusted EBITDA loss per order, as shown above. Therefore, some investors might have been concerned about whether the company's plate is getting too much to handle. Over the last three months, the company has entered into new markets such as India, France, Spain, and Poland. They are in addition to its battle with MercadoLibre (MELI) in Latin America, particularly Brazil. As a result, there are concerns on whether Sea Limited could continue its adroit execution in these markets while still making losses. We believe such concerns are valid. However, Sea Limited has shown its tremendous capability in penetrating the most important markets where the incumbents have strong leadership. It includes Lazada (BABA) in Southeast Asia, MercadoLibre in Brazil, and Tokopedia in Indonesia. Shopee was never the first-mover. But, it took advantage as the \"late-comer\" as it sought to compete with the incumbents. It's important to note that Sea Limited is not averse to competition. It has thrived against the incumbents and has made the e-commerce space in these geographical regions much more competitive.\nSea Limited revised adjusted EPS mean consensus estimates. Data source: S&P Capital IQ, Seeking Alpha\nNevertheless, the road towards profitability might be stretched further due to its e-commerce expansion. Readers can quickly glance over the chart above, where its adjusted EPS estimates have been revised downwards through FY23 over the last five months. However, we believe that if you are a long-term investor with a five-year horizon at least, it's not a cause for concern. Earlier investors in Sea Limited can keenly recall the company's massive adjusted EBITDA per order losses, as seen in the previous chart. Shopee has scaled tremendously over the last five years and has improved its operating leverage further. But, it's important to note that it takes time to scale up. Therefore, earlier losses in new geographical markets are expected. But, management has demonstrated its execution capability over the last three years. Considering its much reduced adjusted EBITDA losses over the previous few years, we believe that Shopee is even better positioned than before to navigate its expansion.\nSo, is SE Stock a Buy Now?\nSE stock EV/NTM Revenue 4Y mean.\nSE stock is trading at an EV/NTM Revenue of 8.3x. Therefore, it has brought it back to its 4Y NTM revenue multiple mean of 8.6x. We believe there's a fantastic opportunity right now as the market has undoubtedly overreacted. As demonstrated clearly, SE is still expected to generate massive revenue growth moving ahead, even though it means the road to profitability gets further extended.\nConsidering its FY23 revenue estimate, SE stock is trading at just 5.8x FY23 revenue. No one can accurately predict where the stock will be headed over the next few months. But, we think it represents a tremendous opportunity right now.\nSE stock price target Vs. actual price trend. Source: Seeking Alpha\nMoreover, readers can observe that the valuation gap between SE stock's consensus price target (PT) of $405.87 and its current price has never been more significant in a while. It's even more pronounced than its last significant correction in April/May. Notably, the consensus price target has been revised upwards despite the so-called \"gaming headwinds.\" And, if you look at the price chart, SE stock price has followed the revised PT trend very consistently over time. Therefore, the current price could be one of the most significant discounts you could observe in a long time.\nSE stock DCF valuation model. Data source: S&P Capital IQ, company filings, author\nOur DCF model also shows that SE stock is now significantly undervalued with an implied fair value of $371.46. We have also used reasonable estimates in our model. Moreover, we believe that SE will continue to gain significant operating leverage as it scales in the new markets. We estimate that its adjusted EBITDA margins could reach 15% by FY25.\nLastly, the stock is also testing a critical support level that has strongly underpinned the stock's advance since early 2021. Therefore, there are sufficient reasons to believe that the current entry point to add exposure to SE stock seems very attractive now.\nConsequently,we revise our rating on SE stock to Strong Buy.","news_type":1,"symbols_score_info":{"SE":0.9}},"isVote":1,"tweetType":1,"viewCount":2904,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870875362,"gmtCreate":1636606055556,"gmtModify":1636606055556,"author":{"id":"3567674825770783","authorId":"3567674825770783","name":"Racheling89","avatar":"https://static.tigerbbs.com/840f90f6593eaeda4fa762b7d02d006d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567674825770783","idStr":"3567674825770783"},"themes":[],"title":"","htmlText":"To the moon!!! ","listText":"To the moon!!! ","text":"To the moon!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/870875362","repostId":"2182039707","repostType":4,"isVote":1,"tweetType":1,"viewCount":3456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":839115080,"gmtCreate":1629126345540,"gmtModify":1633687190370,"author":{"id":"3567674825770783","authorId":"3567674825770783","name":"Racheling89","avatar":"https://static.tigerbbs.com/840f90f6593eaeda4fa762b7d02d006d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567674825770783","idStr":"3567674825770783"},"themes":[],"title":"","htmlText":"prepare your $$$","listText":"prepare your $$$","text":"prepare your $$$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/839115080","repostId":"1112885056","repostType":4,"repost":{"id":"1112885056","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629120408,"share":"https://www.laohunote.com/m/news/1112885056?lang=zh_CN&edition=full","pubTime":"2021-08-16 21:26","market":"us","language":"en","title":"U.S. stock market opens lower Monday amid weak China demand, spread of delta variant<blockquote>由于中国需求疲软和德尔塔变异毒株蔓延，美国股市周一开盘走低</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1112885056","media":"Tiger Newspress","summary":"(Aug 16) U.S. stock market opens lower Monday amid weak China demand, spread of delta variant.\nDow, ","content":"<p>(Aug 16) U.S. stock market opens lower Monday amid weak China demand, spread of delta variant.</p><p><blockquote>（8月16日）美国由于中国需求疲软和德尔塔变异毒株蔓延，股市周一开盘走低。</blockquote></p><p> Dow, S&P 500, Nasdaq Composite off 0.3% in early Monday action.</p><p><blockquote>道琼斯综合指数、标普500综合指数、纳斯达克综合指数周一早盘下跌 0.3%。</blockquote></p><p> Data showed Chinese economic growth slowing more than expected. China’s retail salesincreased by 8.5% in Julyyear-over-year, below the 11.5% forecast from economists polled by Reuters. Online sales gained just 4.4% for the month. On the manufacturing sector in the country, industrial production increased by 6.4%, below the 7.8% consensus estimate.</p><p><blockquote>数据显示，中国经济增长放缓幅度超过预期。中国7月份零售额同比增长8.5%，低于路透社调查的经济学家预测的11.5%。当月在线销售额仅增长 4.4%。该国制造业方面，工业生产增长6.4%，低于7.8%的普遍预期。</blockquote></p><p> The country’s National Bureau of Statistics noted an impact from Covid and domestic flooding, saying the country’s “economic recovery is still unstable and uneven.”</p><p><blockquote>该国国家统计局指出了科维德和国内洪水的影响，称该国 “经济复苏仍然不稳定和不均衡”。</blockquote></p><p> “Delta driven slowdown grips China,” wrote CNBC’s Jim Cramer in a tweet. “Not sure of impact here yet.”</p><p><blockquote>“CNBC 的吉姆-克莱默（Jim Cramer）在一条推文中写道：”三角洲驱动的经济放缓笼罩着中国。“还不确定对这里的影响”。</blockquote></p><p> Shares of stocks linked to a fast-recovering economy were weak in morning trading. Shares of Caterpillar, Freeport-McMoRan and Nucor dipped.</p><p><blockquote>与经济快速复苏相关的股票在早盘交易中表现疲软。卡特彼勒、自由港麦克莫兰和纽柯的股价下跌。</blockquote></p><p> U.S. stocks also pulled back amid growing support within the Federal Reserveto announce a tapering of its bond purchases in Septemberand begin the reduction in buying a month or so after. Interviews with central bank officials along with their public comments show growing support for a faster taper timeline than markets had expected a month ago.</p><p><blockquote>由于美联储内部日益增长的支持，美国股市也出现回落，美联储宣布在 9 月份缩减债券购买规模，并在一个月左右开始减少购买规模。对央行官员的采访以及他们的公开评论显示，越来越多的人支持比市场一个月前预期的更快的缩减时间表。</blockquote></p><p> The yield on the benchmark 10-year Treasury note dipped to 1.248%. Bond yields fall as their prices rise.</p><p><blockquote>基准10年期国债收益率跌至1.248%。债券收益率随着价格上涨而下降。</blockquote></p><p> Tesla’s stock retreated Monday after the National Highway Traffic Safety Administration announced aformal probeinto the electric vehicle maker’s Autopilot partially automated driving system.</p><p><blockquote>在美国国家公路交通安全管理局（National Highway Traffic Safety Administration）宣布对这家电动汽车制造商的 Autopilot 半自动驾驶系统进行非正式调查后，特斯拉股价周一回落。</blockquote></p><p> The Dow ended last week at 35,515.38, a record close, while theS&P 500finished Friday at 4,468.00 to notch its own best-ever finish.</p><p><blockquote>道琼斯指数上周收于 35,515.38 点，创下历史新高，而标准普尔 500 指数周五收于 4,468.00 点，创下历史最佳收盘价。</blockquote></p><p> The blue-chip Dow and the S&P 500 rounded out the week with muted gains of 0.8% and 0.7%, respectively, amid light summertime trading volumes. The tech-heavy Nasdaq Composite underperformed week, down just under 0.1%.</p><p><blockquote>由于夏季交易量清淡，蓝筹股道琼斯指数和标普500指数本周分别小幅上涨 0.8% 和 0.7%。以科技股为主的纳斯达克综合指数本周表现不佳，下跌略低于 0.1%。</blockquote></p><p> The major stock indexes for much of the last month have ground to new records on the back of robust corporate earnings results. The S&P 500 has closed at a record high 48 times this year out of 155 trading days, or 31% of the time — the most frequent closing highs on record back to 1950.</p><p><blockquote>由于强劲的企业盈利结果，上个月大部分时间里，主要股指都创下了新纪录。标普500今年在 155 个交易日中有 48 次收于历史新高，占 31%，这是自 1950 年以来最频繁的收盘高点。</blockquote></p><p> Eighty-seven percent of S&P 500 companies have reported positive earnings per share surprises for the second calendar quarter, according to FactSet as of Friday. If 87% is the final percentage, it will mark the highest percentage of S&P 500 companies reporting positive EPS surprises since FactSet began tracking this metric in 2008.</p><p><blockquote>根据FactSet周五的数据，87%的标普500公司报告了第二季度的每股收益惊喜。如果最终百分比为 87%，这将标志着自 FactSet 于 2008 年开始跟踪该指标以来，标普500公司报告每股收益意外的最高百分比。</blockquote></p><p> “These are the dog days of August, and low volume and directionless volatility are the order of the moment with 2Q21 earnings season mostly behind us,” Raymond James’ Tavis McCourt said in a note.</p><p><blockquote>“Raymond James 的 Tavis McCourt 在一份报告中说：”现在是八月的三伏天，随着2021年第二季度财报季基本过去，低交易量和无方向的波动是目前的趋势。</blockquote></p><p> Investors await quarterly earnings reports frommajor retailersthis week including Home Depot, Walmart, Target and Lowe’s.</p><p><blockquote>投资者正在等待本周家得宝（Home Depot）、沃尔玛（Walmart）、塔吉特（Target）和劳氏（Lowe's）等主要零售商的季度财报。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stock market opens lower Monday amid weak China demand, spread of delta variant<blockquote>由于中国需求疲软和德尔塔变异毒株蔓延，美国股市周一开盘走低</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stock market opens lower Monday amid weak China demand, spread of delta variant<blockquote>由于中国需求疲软和德尔塔变异毒株蔓延，美国股市周一开盘走低</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-16 21:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Aug 16) U.S. stock market opens lower Monday amid weak China demand, spread of delta variant.</p><p><blockquote>（8月16日）美国由于中国需求疲软和德尔塔变异毒株蔓延，股市周一开盘走低。</blockquote></p><p> Dow, S&P 500, Nasdaq Composite off 0.3% in early Monday action.</p><p><blockquote>道琼斯综合指数、标普500综合指数、纳斯达克综合指数周一早盘下跌 0.3%。</blockquote></p><p> Data showed Chinese economic growth slowing more than expected. China’s retail salesincreased by 8.5% in Julyyear-over-year, below the 11.5% forecast from economists polled by Reuters. Online sales gained just 4.4% for the month. On the manufacturing sector in the country, industrial production increased by 6.4%, below the 7.8% consensus estimate.</p><p><blockquote>数据显示，中国经济增长放缓幅度超过预期。中国7月份零售额同比增长8.5%，低于路透社调查的经济学家预测的11.5%。当月在线销售额仅增长 4.4%。该国制造业方面，工业生产增长6.4%，低于7.8%的普遍预期。</blockquote></p><p> The country’s National Bureau of Statistics noted an impact from Covid and domestic flooding, saying the country’s “economic recovery is still unstable and uneven.”</p><p><blockquote>该国国家统计局指出了科维德和国内洪水的影响，称该国 “经济复苏仍然不稳定和不均衡”。</blockquote></p><p> “Delta driven slowdown grips China,” wrote CNBC’s Jim Cramer in a tweet. “Not sure of impact here yet.”</p><p><blockquote>“CNBC 的吉姆-克莱默（Jim Cramer）在一条推文中写道：”三角洲驱动的经济放缓笼罩着中国。“还不确定对这里的影响”。</blockquote></p><p> Shares of stocks linked to a fast-recovering economy were weak in morning trading. Shares of Caterpillar, Freeport-McMoRan and Nucor dipped.</p><p><blockquote>与经济快速复苏相关的股票在早盘交易中表现疲软。卡特彼勒、自由港麦克莫兰和纽柯的股价下跌。</blockquote></p><p> U.S. stocks also pulled back amid growing support within the Federal Reserveto announce a tapering of its bond purchases in Septemberand begin the reduction in buying a month or so after. Interviews with central bank officials along with their public comments show growing support for a faster taper timeline than markets had expected a month ago.</p><p><blockquote>由于美联储内部日益增长的支持，美国股市也出现回落，美联储宣布在 9 月份缩减债券购买规模，并在一个月左右开始减少购买规模。对央行官员的采访以及他们的公开评论显示，越来越多的人支持比市场一个月前预期的更快的缩减时间表。</blockquote></p><p> The yield on the benchmark 10-year Treasury note dipped to 1.248%. Bond yields fall as their prices rise.</p><p><blockquote>基准10年期国债收益率跌至1.248%。债券收益率随着价格上涨而下降。</blockquote></p><p> Tesla’s stock retreated Monday after the National Highway Traffic Safety Administration announced aformal probeinto the electric vehicle maker’s Autopilot partially automated driving system.</p><p><blockquote>在美国国家公路交通安全管理局（National Highway Traffic Safety Administration）宣布对这家电动汽车制造商的 Autopilot 半自动驾驶系统进行非正式调查后，特斯拉股价周一回落。</blockquote></p><p> The Dow ended last week at 35,515.38, a record close, while theS&P 500finished Friday at 4,468.00 to notch its own best-ever finish.</p><p><blockquote>道琼斯指数上周收于 35,515.38 点，创下历史新高，而标准普尔 500 指数周五收于 4,468.00 点，创下历史最佳收盘价。</blockquote></p><p> The blue-chip Dow and the S&P 500 rounded out the week with muted gains of 0.8% and 0.7%, respectively, amid light summertime trading volumes. The tech-heavy Nasdaq Composite underperformed week, down just under 0.1%.</p><p><blockquote>由于夏季交易量清淡，蓝筹股道琼斯指数和标普500指数本周分别小幅上涨 0.8% 和 0.7%。以科技股为主的纳斯达克综合指数本周表现不佳，下跌略低于 0.1%。</blockquote></p><p> The major stock indexes for much of the last month have ground to new records on the back of robust corporate earnings results. The S&P 500 has closed at a record high 48 times this year out of 155 trading days, or 31% of the time — the most frequent closing highs on record back to 1950.</p><p><blockquote>由于强劲的企业盈利结果，上个月大部分时间里，主要股指都创下了新纪录。标普500今年在 155 个交易日中有 48 次收于历史新高，占 31%，这是自 1950 年以来最频繁的收盘高点。</blockquote></p><p> Eighty-seven percent of S&P 500 companies have reported positive earnings per share surprises for the second calendar quarter, according to FactSet as of Friday. If 87% is the final percentage, it will mark the highest percentage of S&P 500 companies reporting positive EPS surprises since FactSet began tracking this metric in 2008.</p><p><blockquote>根据FactSet周五的数据，87%的标普500公司报告了第二季度的每股收益惊喜。如果最终百分比为 87%，这将标志着自 FactSet 于 2008 年开始跟踪该指标以来，标普500公司报告每股收益意外的最高百分比。</blockquote></p><p> “These are the dog days of August, and low volume and directionless volatility are the order of the moment with 2Q21 earnings season mostly behind us,” Raymond James’ Tavis McCourt said in a note.</p><p><blockquote>“Raymond James 的 Tavis McCourt 在一份报告中说：”现在是八月的三伏天，随着2021年第二季度财报季基本过去，低交易量和无方向的波动是目前的趋势。</blockquote></p><p> Investors await quarterly earnings reports frommajor retailersthis week including Home Depot, Walmart, Target and Lowe’s.</p><p><blockquote>投资者正在等待本周家得宝（Home Depot）、沃尔玛（Walmart）、塔吉特（Target）和劳氏（Lowe's）等主要零售商的季度财报。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112885056","content_text":"(Aug 16) U.S. stock market opens lower Monday amid weak China demand, spread of delta variant.\nDow, S&P 500, Nasdaq Composite off 0.3% in early Monday action.\nData showed Chinese economic growth slowing more than expected. China’s retail salesincreased by 8.5% in Julyyear-over-year, below the 11.5% forecast from economists polled by Reuters. Online sales gained just 4.4% for the month. On the manufacturing sector in the country, industrial production increased by 6.4%, below the 7.8% consensus estimate.\nThe country’s National Bureau of Statistics noted an impact from Covid and domestic flooding, saying the country’s “economic recovery is still unstable and uneven.”\n“Delta driven slowdown grips China,” wrote CNBC’s Jim Cramer in a tweet. “Not sure of impact here yet.”\nShares of stocks linked to a fast-recovering economy were weak in morning trading. Shares of Caterpillar, Freeport-McMoRan and Nucor dipped.\nU.S. stocks also pulled back amid growing support within the Federal Reserveto announce a tapering of its bond purchases in Septemberand begin the reduction in buying a month or so after. Interviews with central bank officials along with their public comments show growing support for a faster taper timeline than markets had expected a month ago.\nThe yield on the benchmark 10-year Treasury note dipped to 1.248%. Bond yields fall as their prices rise.\nTesla’s stock retreated Monday after the National Highway Traffic Safety Administration announced aformal probeinto the electric vehicle maker’s Autopilot partially automated driving system.\nThe Dow ended last week at 35,515.38, a record close, while theS&P 500finished Friday at 4,468.00 to notch its own best-ever finish.\nThe blue-chip Dow and the S&P 500 rounded out the week with muted gains of 0.8% and 0.7%, respectively, amid light summertime trading volumes. The tech-heavy Nasdaq Composite underperformed week, down just under 0.1%.\nThe major stock indexes for much of the last month have ground to new records on the back of robust corporate earnings results. The S&P 500 has closed at a record high 48 times this year out of 155 trading days, or 31% of the time — the most frequent closing highs on record back to 1950.\nEighty-seven percent of S&P 500 companies have reported positive earnings per share surprises for the second calendar quarter, according to FactSet as of Friday. If 87% is the final percentage, it will mark the highest percentage of S&P 500 companies reporting positive EPS surprises since FactSet began tracking this metric in 2008.\n“These are the dog days of August, and low volume and directionless volatility are the order of the moment with 2Q21 earnings season mostly behind us,” Raymond James’ Tavis McCourt said in a note.\nInvestors await quarterly earnings reports frommajor retailersthis week including Home Depot, Walmart, Target and Lowe’s.","news_type":1,"symbols_score_info":{"SPY":0.9,".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2379,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894095378,"gmtCreate":1628776869194,"gmtModify":1633689584518,"author":{"id":"3567674825770783","authorId":"3567674825770783","name":"Racheling89","avatar":"https://static.tigerbbs.com/840f90f6593eaeda4fa762b7d02d006d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567674825770783","idStr":"3567674825770783"},"themes":[],"title":"","htmlText":"Agree!!! Please like","listText":"Agree!!! Please like","text":"Agree!!! Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894095378","repostId":"2158709252","repostType":4,"isVote":1,"tweetType":1,"viewCount":3811,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892567107,"gmtCreate":1628673796609,"gmtModify":1633745217329,"author":{"id":"3567674825770783","authorId":"3567674825770783","name":"Racheling89","avatar":"https://static.tigerbbs.com/840f90f6593eaeda4fa762b7d02d006d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567674825770783","idStr":"3567674825770783"},"themes":[],"title":"","htmlText":"Nice~ please help to like~ thanks!","listText":"Nice~ please help to like~ thanks!","text":"Nice~ please help to like~ thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/892567107","repostId":"1172810796","repostType":4,"repost":{"id":"1172810796","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628671712,"share":"https://www.laohunote.com/m/news/1172810796?lang=zh_CN&edition=full","pubTime":"2021-08-11 16:48","market":"us","language":"en","title":"BioCryst shares jumped 10.49% in premarket trading,as withdrawing previous stock offering.<blockquote>BioCryst 股价在盘前交易中上涨 10.49%，撤回之前的股票发行。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172810796","media":"Tiger Newspress","summary":"BioCryst shares jumped 10.49% in premarket trading,as withdrawing previous stock offering.\nBioCryst ","content":"<p>BioCryst shares jumped 10.49% in premarket trading,as withdrawing previous stock offering.</p><p><blockquote>BioCryst 股价在盘前交易中上涨 10.49%，撤回之前的股票发行。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c15bfde15a241770cbb0410850f6460f\" tg-width=\"900\" tg-height=\"624\" referrerpolicy=\"no-referrer\">BioCryst Pharmaceuticals, Inc. announced today that it has withdrawn its proposed public offering. With our strong balance sheet, and increasing revenues from ORLADEYO<b>®</b> (berotralstat), we believe that current market conditions are not conducive to an offering on terms that would be in the best interests of our current stockholders. We are well capitalized, with cash, cash equivalents, restricted cash and investments of $222.8 million as of June 30, 2021. Based on our expectations for revenue, operating expenses, and our option to access an additional $75 million from our existing credit facility, we believe our current cash runway takes us into 2023.</p><p><blockquote>BioCryst Pharmaceuticals, Inc. 今天宣布撤回拟议的公开募股。凭借我们强劲的资产负债表和 ORLADEYO 不断增长的收入<b>®</b>（berotralstat），我们认为当前的市场条件不利于以符合我们现有股东最佳利益的条款进行发行。截至 2021 年 6 月 30 日，我们的资本充足，拥有现金、现金等价物、受限制现金和投资 2.228 亿美元。根据我们对收入、运营费用的预期，以及我们从现有信贷额度中额外获得 7500 万美元的选择，我们相信我们目前的现金跑道将带我们进入 2023 年。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCryst shares jumped 10.49% in premarket trading,as withdrawing previous stock offering.<blockquote>BioCryst 股价在盘前交易中上涨 10.49%，撤回之前的股票发行。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCryst shares jumped 10.49% in premarket trading,as withdrawing previous stock offering.<blockquote>BioCryst 股价在盘前交易中上涨 10.49%，撤回之前的股票发行。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-11 16:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BioCryst shares jumped 10.49% in premarket trading,as withdrawing previous stock offering.</p><p><blockquote>BioCryst 股价在盘前交易中上涨 10.49%，撤回之前的股票发行。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c15bfde15a241770cbb0410850f6460f\" tg-width=\"900\" tg-height=\"624\" referrerpolicy=\"no-referrer\">BioCryst Pharmaceuticals, Inc. announced today that it has withdrawn its proposed public offering. With our strong balance sheet, and increasing revenues from ORLADEYO<b>®</b> (berotralstat), we believe that current market conditions are not conducive to an offering on terms that would be in the best interests of our current stockholders. We are well capitalized, with cash, cash equivalents, restricted cash and investments of $222.8 million as of June 30, 2021. Based on our expectations for revenue, operating expenses, and our option to access an additional $75 million from our existing credit facility, we believe our current cash runway takes us into 2023.</p><p><blockquote>BioCryst Pharmaceuticals, Inc. 今天宣布撤回拟议的公开募股。凭借我们强劲的资产负债表和 ORLADEYO 不断增长的收入<b>®</b>（berotralstat），我们认为当前的市场条件不利于以符合我们现有股东最佳利益的条款进行发行。截至 2021 年 6 月 30 日，我们的资本充足，拥有现金、现金等价物、受限制现金和投资 2.228 亿美元。根据我们对收入、运营费用的预期，以及我们从现有信贷额度中额外获得 7500 万美元的选择，我们相信我们目前的现金跑道将带我们进入 2023 年。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCRX":"BioCryst制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172810796","content_text":"BioCryst shares jumped 10.49% in premarket trading,as withdrawing previous stock offering.\nBioCryst Pharmaceuticals, Inc. announced today that it has withdrawn its proposed public offering. With our strong balance sheet, and increasing revenues from ORLADEYO® (berotralstat), we believe that current market conditions are not conducive to an offering on terms that would be in the best interests of our current stockholders. We are well capitalized, with cash, cash equivalents, restricted cash and investments of $222.8 million as of June 30, 2021. Based on our expectations for revenue, operating expenses, and our option to access an additional $75 million from our existing credit facility, we believe our current cash runway takes us into 2023.","news_type":1,"symbols_score_info":{"BCRX":0.9}},"isVote":1,"tweetType":1,"viewCount":2712,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892565035,"gmtCreate":1628673647627,"gmtModify":1631884773533,"author":{"id":"3567674825770783","authorId":"3567674825770783","name":"Racheling89","avatar":"https://static.tigerbbs.com/840f90f6593eaeda4fa762b7d02d006d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567674825770783","idStr":"3567674825770783"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/CRWD\">$CrowdStrike Holdings, Inc.(CRWD)$</a>Yeah!","listText":"<a href=\"https://laohu8.com/S/CRWD\">$CrowdStrike Holdings, Inc.(CRWD)$</a>Yeah!","text":"$CrowdStrike Holdings, Inc.(CRWD)$Yeah!","images":[{"img":"https://static.tigerbbs.com/cb276fec7766a0b4d75fefe4cbaa84f1","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/892565035","isVote":1,"tweetType":1,"viewCount":2165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":892566865,"gmtCreate":1628673542957,"gmtModify":1633745219064,"author":{"id":"3567674825770783","authorId":"3567674825770783","name":"Racheling89","avatar":"https://static.tigerbbs.com/840f90f6593eaeda4fa762b7d02d006d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567674825770783","idStr":"3567674825770783"},"themes":[],"title":"","htmlText":"Let’s hope it drops more to buy in!! ","listText":"Let’s hope it drops more to buy in!! ","text":"Let’s hope it drops more to buy in!!","images":[{"img":"https://static.tigerbbs.com/e6ff1ea5985f2a8e82a5fd4c0e77a8c4","width":"1125","height":"2992"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/892566865","isVote":1,"tweetType":1,"viewCount":3265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":890389191,"gmtCreate":1628083331513,"gmtModify":1631884773549,"author":{"id":"3567674825770783","authorId":"3567674825770783","name":"Racheling89","avatar":"https://static.tigerbbs.com/840f90f6593eaeda4fa762b7d02d006d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567674825770783","idStr":"3567674825770783"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/CRWD\">$CrowdStrike Holdings, Inc.(CRWD)$</a>Holding for long term ","listText":"<a href=\"https://laohu8.com/S/CRWD\">$CrowdStrike Holdings, Inc.(CRWD)$</a>Holding for long term ","text":"$CrowdStrike Holdings, Inc.(CRWD)$Holding for long term","images":[{"img":"https://static.tigerbbs.com/230f46db79a706343674e61743cb96d4","width":"1125","height":"2183"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/890389191","isVote":1,"tweetType":1,"viewCount":2165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":890317286,"gmtCreate":1628083218945,"gmtModify":1633753781766,"author":{"id":"3567674825770783","authorId":"3567674825770783","name":"Racheling89","avatar":"https://static.tigerbbs.com/840f90f6593eaeda4fa762b7d02d006d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567674825770783","idStr":"3567674825770783"},"themes":[],"title":"","htmlText":"Nvax is running pre-market!!! Please like 👍🏻 ","listText":"Nvax is running pre-market!!! Please like 👍🏻 ","text":"Nvax is running pre-market!!! Please like 👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/890317286","repostId":"1124757232","repostType":2,"repost":{"id":"1124757232","kind":"news","pubTimestamp":1628045612,"share":"https://www.laohunote.com/m/news/1124757232?lang=zh_CN&edition=full","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical 和 Novavax 的股票在 2021 年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Pfizer might surprise to the upside.</li> <li>Inari Medical is growing like gangbusters.</li> <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞公司可能会感到惊讶。</li><li>Inari Medical 正在像破坏者一样成长。</li><li>随着 COVID-19 病毒的变异，Novavax 的疫苗可能是一种重要的加强注射。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待着正常化。但COVID正在变异，新德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>一个由 Motley Fool 撰稿人组成的小组为医疗保健股提供了三个想法，即使 COVID 情况变得更糟，这些股票也将在 2021 年上涨。阅读更多内容，了解为什么您可能想要购买股票<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">稻荷医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b> <b>(Pfizer):</b> American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> -- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更大的运行空间</b></h3><b>乔治·布德威尔</b> <b>（辉瑞）：</b>美国制药巨头辉瑞在目前的新冠疫苗参与者中听起来可能不是一个性感的选择。华尔街目前的共识是制药商的疫苗 Comirnaty——与<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>-- 从 2022 年开始，从销售角度来看，势头将会减弱。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty 的商业寿命可能会比最初预期的长得多。虽然高度传播变种的出现对整个社会来说显然是一个可怕的消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因 delta 问题而走高。首先也是最重要的，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。第二，辉瑞计划本月开始针对delta特异性版本的疫苗进行临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品和药物管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞公司已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株病毒的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对投资者来说，大局是辉瑞 2022 年的收入可能比 2021 年增长多达 9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了 delta 特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比 2021 年下降 14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.</p><p><blockquote>辉瑞的股票可能会走向何方？从保守的角度来看，如果疫苗方面的所有因素都到位，股价应该达到 50 美元。这比该制药商的股价目前上涨了约 17%，这甚至还没有考虑到该公司目前水平下诱人的 3.64% 股息收益率。简而言之，如果这种情况发生，辉瑞的股票交易价格将仅为 2022 年销售额的 3.5 倍左右，这对于支付股息的大型制药股来说是一个相当温和的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b> <b>(Inari Medical):</b> If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to <i>The New York Times</i> -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>稻荷医疗：销售额飙升</b></h3><b>帕特里克·巴富马</b> <b>（稻荷医疗）：</b>如果您正在寻找一只在疫情的顺风消退后具有持久动力的股票，请关注 Inari Medical。根据数据，2021 年 7 月 27 日新增 108,000 例新冠病例，为 2021 年 2 月 5 日以来最多<i>纽约时报</i>-- 这个数字是 7 月初七天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者致残和潜在威胁生命的血栓风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否可以完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在去除大血栓，而不需要强效的血栓破除药物。通过使用其ClotTriever和FlowTriever设备，Inari迄今已治疗了超过25,000名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500例手术，比去年同期增长130%，比2020年第四季度高出约20%。根据数据，截至 7 月 27 日，约 12% 的入院 COVID 患者出现血栓，美国约有 35,000 名 COVID 住院病人（并且还在增加）<i>泰晤士报</i>Inari 可能会看到符合条件的案件数量有所增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的成果非常惊人：</blockquote></p><p> <ul> <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li> <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li> <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li> <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>肺部中高危血栓的历史30天死亡率为9.7%，Inari 0.4%的30天死亡率令人印象深刻。</li><li>与常规护理的24.4%相比，30天再入院率下降了6.7%。</li><li>48小时内发生重大不良事件的发生率仅为1.3%。</li><li>手术后不需要在ICU住院。</li></ul>把所有这些加起来，Inari的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，Inari 的市销率为 18，使其成为待售的成长型股票。</blockquote></p><p> Inari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari 在价值 38 亿美元的美国市场的渗透率不到 5%，而且在今年早些时候推出的欧洲也有很大的增长空间。这意味着这家市值 45 亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性手术，但它显然没有减缓Inari的速度，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b> <b>(Novavax):</b> The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能升到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司 Novavax 在 2020 年表现出色，由于对其 COVID 疫苗的乐观情绪，其股价上涨了 2,700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股上涨了60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19 疫苗的积极第三阶段数据导致该股在年初飙升，但由于该公司将疫苗推向市场出现延误，股价已回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同制造设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管有这些延迟，长期投资者仍有理由看涨。制造业正在扩大规模，预计到第三季度末产量将达到每月 1 亿剂，到 12 月产量将达到每月 1.5 亿剂。虽然美国许多人已经接种了疫苗，但世界其他地区的机会是巨大的。Novavax 已向 COVAX（国际疫苗财团）预售了 11 亿剂疫苗，并已签约在全球供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told <i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用作已经接种疫苗的人的加强注射。F.D.A. 代理首席科学家卢西亚娜·博里奥 (Luciana Borio) 博士表示：“它们可能确实是加强剂的合适选择。”2015年至2017年，被告知<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax 计划将其 COVID 疫苗与流感疫苗结合起来，形成一次性注射方案。虽然COVID的变异速度不如流感快，但在过去的一年里，我们已经看到了几种变异菌株。在未来几年，我们很可能需要接种不止一次疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-08-04 10:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical 和 Novavax 的股票在 2021 年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Pfizer might surprise to the upside.</li> <li>Inari Medical is growing like gangbusters.</li> <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞公司可能会感到惊讶。</li><li>Inari Medical 正在像破坏者一样成长。</li><li>随着 COVID-19 病毒的变异，Novavax 的疫苗可能是一种重要的加强注射。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待着正常化。但COVID正在变异，新德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>一个由 Motley Fool 撰稿人组成的小组为医疗保健股提供了三个想法，即使 COVID 情况变得更糟，这些股票也将在 2021 年上涨。阅读更多内容，了解为什么您可能想要购买股票<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">稻荷医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b> <b>(Pfizer):</b> American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> -- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更大的运行空间</b></h3><b>乔治·布德威尔</b> <b>（辉瑞）：</b>美国制药巨头辉瑞在目前的新冠疫苗参与者中听起来可能不是一个性感的选择。华尔街目前的共识是制药商的疫苗 Comirnaty——与<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>-- 从 2022 年开始，从销售角度来看，势头将会减弱。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty 的商业寿命可能会比最初预期的长得多。虽然高度传播变种的出现对整个社会来说显然是一个可怕的消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因 delta 问题而走高。首先也是最重要的，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。第二，辉瑞计划本月开始针对delta特异性版本的疫苗进行临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品和药物管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞公司已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株病毒的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对投资者来说，大局是辉瑞 2022 年的收入可能比 2021 年增长多达 9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了 delta 特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比 2021 年下降 14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.</p><p><blockquote>辉瑞的股票可能会走向何方？从保守的角度来看，如果疫苗方面的所有因素都到位，股价应该达到 50 美元。这比该制药商的股价目前上涨了约 17%，这甚至还没有考虑到该公司目前水平下诱人的 3.64% 股息收益率。简而言之，如果这种情况发生，辉瑞的股票交易价格将仅为 2022 年销售额的 3.5 倍左右，这对于支付股息的大型制药股来说是一个相当温和的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b> <b>(Inari Medical):</b> If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to <i>The New York Times</i> -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>稻荷医疗：销售额飙升</b></h3><b>帕特里克·巴富马</b> <b>（稻荷医疗）：</b>如果您正在寻找一只在疫情的顺风消退后具有持久动力的股票，请关注 Inari Medical。根据数据，2021 年 7 月 27 日新增 108,000 例新冠病例，为 2021 年 2 月 5 日以来最多<i>纽约时报</i>-- 这个数字是 7 月初七天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者致残和潜在威胁生命的血栓风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否可以完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在去除大血栓，而不需要强效的血栓破除药物。通过使用其ClotTriever和FlowTriever设备，Inari迄今已治疗了超过25,000名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500例手术，比去年同期增长130%，比2020年第四季度高出约20%。根据数据，截至 7 月 27 日，约 12% 的入院 COVID 患者出现血栓，美国约有 35,000 名 COVID 住院病人（并且还在增加）<i>泰晤士报</i>Inari 可能会看到符合条件的案件数量有所增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的成果非常惊人：</blockquote></p><p> <ul> <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li> <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li> <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li> <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>肺部中高危血栓的历史30天死亡率为9.7%，Inari 0.4%的30天死亡率令人印象深刻。</li><li>与常规护理的24.4%相比，30天再入院率下降了6.7%。</li><li>48小时内发生重大不良事件的发生率仅为1.3%。</li><li>手术后不需要在ICU住院。</li></ul>把所有这些加起来，Inari的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，Inari 的市销率为 18，使其成为待售的成长型股票。</blockquote></p><p> Inari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari 在价值 38 亿美元的美国市场的渗透率不到 5%，而且在今年早些时候推出的欧洲也有很大的增长空间。这意味着这家市值 45 亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性手术，但它显然没有减缓Inari的速度，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b> <b>(Novavax):</b> The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能升到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司 Novavax 在 2020 年表现出色，由于对其 COVID 疫苗的乐观情绪，其股价上涨了 2,700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股上涨了60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19 疫苗的积极第三阶段数据导致该股在年初飙升，但由于该公司将疫苗推向市场出现延误，股价已回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同制造设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管有这些延迟，长期投资者仍有理由看涨。制造业正在扩大规模，预计到第三季度末产量将达到每月 1 亿剂，到 12 月产量将达到每月 1.5 亿剂。虽然美国许多人已经接种了疫苗，但世界其他地区的机会是巨大的。Novavax 已向 COVAX（国际疫苗财团）预售了 11 亿剂疫苗，并已签约在全球供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told <i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用作已经接种疫苗的人的加强注射。F.D.A. 代理首席科学家卢西亚娜·博里奥 (Luciana Borio) 博士表示：“它们可能确实是加强剂的合适选择。”2015年至2017年，被告知<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax 计划将其 COVID 疫苗与流感疫苗结合起来，形成一次性注射方案。虽然COVID的变异速度不如流感快，但在过去的一年里，我们已经看到了几种变异菌株。在未来几年，我们很可能需要接种不止一次疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1,"symbols_score_info":{"NVAX":0.9,"NARI":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2894,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159462914,"gmtCreate":1624977279238,"gmtModify":1633946262735,"author":{"id":"3567674825770783","authorId":"3567674825770783","name":"Racheling89","avatar":"https://static.tigerbbs.com/840f90f6593eaeda4fa762b7d02d006d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567674825770783","idStr":"3567674825770783"},"themes":[],"title":"","htmlText":"Vested in Nio! Let’s see Nio in the next 5-10 years! ","listText":"Vested in Nio! Let’s see Nio in the next 5-10 years! ","text":"Vested in Nio! Let’s see Nio in the next 5-10 years!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159462914","repostId":"1124372919","repostType":4,"isVote":1,"tweetType":1,"viewCount":2489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}